Advanced Search

Home > Journals > Giornale Italiano di Dermatologia e Venereologia > Past Issues > Giornale Italiano di Dermatologia e Venereologia 1998 April;133(2) > Giornale Italiano di Dermatologia e Venereologia 1998 April;133(2):79-85

ISSUES AND ARTICLES   MOST READ   eTOC

CURRENT ISSUEGIORNALE ITALIANO DI DERMATOLOGIA E VENEREOLOGIA

A Journal on Dermatology and Sexually Transmitted Diseases


Official Journal of the Italian Society of Dermatology and Sexually Transmitted Diseases
Indexed/Abstracted in: EMBASE, PubMed/MEDLINE, Science Citation Index Expanded (SciSearch), Scopus
Impact Factor 1,014

 

Giornale Italiano di Dermatologia e Venereologia 1998 April;133(2):79-85

 ORIGINAL ARTICLES

Top­ical aze­laic ­acid ­therapy for pal­pe­bral ­lesions of mel­a­noma in ­situ (len­tigo ­maligna) and for mel­a­noma in ­situ pro­gressed to inva­sive mel­a­noma. A ­report on ­four ­cases

Nazzaro-Porro M. 1, Zina G. 2, Breathnach A. S. 3, Bernengo M. 1, Passi S. 4, Picardo M. 1, Balus L. 1, De Luca C. 4

1 Isti­tuto Der­mat­o­logico S. Gal­li­cano, ­Rome;
2 ­Clinica Der­mat­o­logica ­dell’Università, ­Turin;
3 Divi­sion of Phys­iology, and Insti­tute of Der­ma­tology, ­UMDS, St. ­Thomas’ Hos­pital ­Campus, ­London, U.K.;
4 ­Centro Invec­chi­a­mento Cel­lu­lare,, Isti­tuto Der­mo­patico ­dell’Immacolata, ­Rome

Aze­laic ­acid has ­been ­shown to ­have a bio­log­ical anti­pro­life­ra­tive and cyto­toxic ­effect on the abnor­mally hyper­ac­tive and malig­nant melan­o­cyte ­both in ­vivo and in ­vitro. ­Here, ben­e­fi­cial ­effects of top­ical aze­laic ­therapy on ­four ­facial ­lesions ­where sur­gery was not con­sid­ered to be a pri­mary or avail­able ­option are ­described. Two ­were ­cases of mel­a­noma in ­situ ­involving the ­lower ­eyelid. In one, com­plete regres­sion of the ­lesion was ­achieved and main­tained for six ­years. In the ­other, the ­overall ­lesional ­area was ­greatly ­reduced, ­allowing dis­crete exci­sion of ­small ­relapses ­with no recur­rences for up to ­nine ­years: ­this ­case dem­on­strates an adju­vant ­effect of aze­laic ­acid ­therapy on sur­gery, in ­reducing the ­overall ­area to be ­excised. The ­other two ­cases ­were of mel­a­noma in ­situ pro­gressed to inva­sive malig­nant mel­a­noma in ­which com­plete clin­ical regres­sion of the ­lesions was ­achieved, in one ­case for up to ­five ­years. Treat­ment in ­these ­cases was essen­tially pal­li­a­tive, ­with pro-b­able pro­lon­ga­tion of ­life in one, and cer­tainly, improve­ment in ­quality of ­remaining ­life in ­both. ­Newer for­mu­la­tions for top­ical appli­ca­tion, pos­sibly com­bined ­with ­oral or ­even ­systemic admin­is­tra­tion, ­could ­lead to ­increased ­delivery of aze­laic ­acid to ­lesional ­sites and reduc­tion in treat­ment ­time ­with sim­ilar ­cases in ­future.

language: English


FULL TEXT  REPRINTS

top of page